Stockscreener 앱 받기
11.17
4.53%
0.4498
Design Therapeutics Inc 주식(DSGN)의 최신 뉴스
Design Therapeutics (DSGN) Gains 2.28% – Approaching Key Resistance at $11.78Weekly Profile - newsline.com
DSGN Q1 2026 Earnings: EPS Beat as Net Loss NarrowsEarnings Expansion Phase - newsline.com
Design Therapeutics Stockholders Approve Director and Auditor at Meeting - TipRanks
Design Therapeutics (DSGN) grants George Simeon 30,000 stock options at $10.55 - Stock Titan
[Form 4] Design Therapeutics, Inc. Insider Trading Activity - Stock Titan
Design Therapeutics (DSGN) director awarded 30,000 options at $10.55 strike - Stock Titan
Director at Design Therapeutics (DSGN) awarded options on 30,000 shares - Stock Titan
Design Therapeutics (DSGN) grants director David Shapiro 30,000 options - Stock Titan
Director at Design Therapeutics (DSGN) awarded 30,000 stock options - Stock Titan
Design Therapeutics (NASDAQ: DSGN) details outcomes of 2026 shareholder meeting votes - Stock Titan
Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components - PR Newswire
DSGN Q1 2026 Earnings: Narrower-than-expected loss highlights cost disciplineSubscription Growth Report - newsline.com
Point72-affiliated holders report 5.1% stake in Design Therapeutics (DSGN) - Stock Titan
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year? - Yahoo Finance
DESIGN THERAPEUTICS INC (DSGN) Stock Chart - ChartMill
DSGN: Early clinical data in Friedreich's ataxia support rapid advancement to registrational studies - TradingView
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics - Business Wire
Design Therapeutics Drops Ahead of Jefferies, Trial Remains in Focus for DSGN - Bez Kabli
Waypoint Bio Raises $20M Series A Led by Amplify Partners to Advance AI-Designed Cell Therapies Toward the Clinic - Business Wire
Design Therapeutics (DSGN) Slides 2.42% as Biotech Stock Tests Key SupportButterfly Setup - The Legal Advocate
Design Therapeutics (DSGN) Dips as Key Support Holds After 2.42% DeclineNaked POC - The Legal Advocate
Design Therapeutics shares jump on encouraging Friedreich ataxia trial results (DSGN) - MSN
Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference - The Manila Times
Biotech Design Therapeutics to join Jefferies 2026 healthcare fireside chat - Stock Titan
Piper Sandler Reaffirms Their Buy Rating on Design Therapeutics (DSGN) - The Globe and Mail
Piper Sandler Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $20 - Moomoo
DSGN Q1 2026 Earnings: Narrower-Than-Expected Loss as Cost Discipline ContinuesPeak Earnings Alert - newsline.com
Design Therapeutics(DSGN) Stock Options Chain | Quotes & News - Moomoo
Design Therapeutics (DSGN) Consolidates Near Support After Marginal DeclineMonthly Profile - The Legal Advocate
Design Therapeutics (DSGN) Holds Steady Near Support as Consolidation PersistsVerified Analyst Reports - Newser
Design Therapeutics Inc. (DSGN) Q1 2026 Earnings: Narrower Loss Surpasses Expectations Amid Quiet QuarterGuidance Accuracy Score - Newser
Design Therapeutics (DSGN) price target increased by 17.05% to 17.51 - MSN
Design Therapeutics (DSGN) Edges Higher as Support Holds Above $10.60Social Trading Insights - Newser
Design Therapeutics Inc. (DSGN) Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Progress in Gene Therapy PipelineRevenue Inflection Point - Newser
Analysts Conflicted on These Healthcare Names: Design Therapeutics (DSGN), Pro Medicus Limited (OtherPMCUF) and Boston Scientific (BSX) - The Globe and Mail
BlossomHill Therapeutics Expands Board of Directors with the Appointments of Sheila Gujrathi, M.D., and John Schmid - The Manila Times
DT-216P2 Shows Dose-Dependent Frataxin Increases and Clinical Improvements After 4 Weeks of IV Dosing in Friedreich Ataxia - Neurology Live
RBC Capital Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $20 - Moomoo
Craig-Hallum Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $22 - Moomoo
Design Therapeutics stock wobbles after rare genetic disease data - MSN
Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich AtaxiaSlideshow (NASDAQ:DSGN) 2026-05-19 - Seeking Alpha
Nasdaq Down 200 Points; Brady Earnings Top Views - Sahm
Crude Oil Gains Over 2%; US Homebuilder Sentiment Increases In May - Sahm
Design Therapeutics (DSGN) Stock Forum and Discussion - Moomoo
Design Therapeutics Stock Wobbles After Rare Genetic Disease Data - Sahm
Design Therapeutics, Inc. Stock 12‑Month Price Target Raised to $20, Implies 39% Upside - TradingView
Design Therapeutics Down Over 25%, on Track for Largest Percent Decrease Since August 2023 -- Data Talk - Moomoo
RBC Capital raises Design Therapeutics price target on trial data By Investing.com - Investing.com Australia
Design Therapeutics Announces Biomarker and Clinical Data from Ongoing Phase 1/2 RESTORE-FA Trial of DT-216P2 in Friedreich Ataxia Patients - Minichart
Design Therapeutics reports positive trial data for FA treatment - Investing.com UK
Design Therapeutics reports positive trial data for FA treatment By Investing.com - Investing.com Australia
RBC Capital raises Design Therapeutics price target on trial data - Investing.com UK
1.79%
0.89%
자본화:
|
볼륨(24시간):